Omada Health Inc(OMDA)

Search documents
Omada Health beats on revenue in first earnings report since IPO
CNBC· 2025-08-07 20:47
Group 1 - The company reported a 49% increase in revenue for Q2, reaching $61 million compared to $41.21 million a year earlier, exceeding analysts' expectations of $55.2 million [1][3] - The net loss for the quarter was $5.31 million, translating to a loss of 24 cents per share, an improvement from a net loss of $10.69 million or $1.40 loss per share in the same period last year [1][3] - CEO Sean Duffy highlighted the company's ability to capitalize on trends in cardiometabolic care and advancements in artificial intelligence as key factors in their performance [2]
Omada Health Reports Second Quarter 2025 Results
Globenewswire· 2025-08-07 20:05
Core Viewpoint - Omada Health, Inc. reported strong financial results for the second quarter of 2025, highlighting a 49% year-over-year revenue growth and significant member growth, indicating progress towards profitability [2][4]. Financial Performance - Revenue reached $61 million, representing a 49% increase compared to the second quarter of 2024 [8]. - Total members grew to 752,000, a 52% increase year-over-year [8]. - Gross margin improved to 66%, up from 60% in the same quarter of the previous year [9]. - Non-GAAP gross margin was 68%, compared to 63% in the second quarter of 2024 [9]. - The net loss narrowed to $5 million, down from a net loss of $11 million in the second quarter of 2024 [9]. - Adjusted EBITDA loss was $0.2 million, significantly improved from a loss of $6.8 million in the same quarter of 2024 [9]. Financial Outlook - For the year ending December 31, 2025, Omada expects revenue in the range of $235 million to $241 million [9]. - Adjusted EBITDA loss is projected to be between $9 million and $5 million [9]. Debt Management - On July 31, 2025, Omada fully repaid $31.0 million in principal and $0.4 million in accrued interest under its term loan facility and revolving line of credit, ahead of schedule [6]. Product and Service Development - The company has seen success with its GLP-1 companion programs, which are now available through two of the largest pharmacy benefit managers in the U.S. [8]. - In May, Omada introduced an AI-agent named OmadaSpark, aimed at providing real-time motivational interviewing and nutrition education to members [8]. Company Background - Omada Health is a virtual-first healthcare provider focused on chronic disease management, with over a decade of experience and a wide customer base exceeding 2,000 clients [11].
Omada Health Inc(OMDA) - 2025 Q2 - Quarterly Results
2025-08-07 20:03
[Second Quarter 2025 Performance Highlights](index=1&type=section&id=Second%20Quarter%202025%20Performance%20Highlights) Omada Health reported strong Q2 2025 results with **49% revenue growth** to $61 million and **52% member growth**, significantly narrowing net and Adjusted EBITDA losses while improving gross margin Q2 2025 Key Financial Metrics (YoY Comparison) | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | **Revenue** | $61 million | $41.2 million | +49% | | **Total Members** | 752,000 | ~495,000 | +52% | | **Gross Margin** | 66% | 60% | +6 p.p. | | **Non-GAAP Gross Margin** | 68% | 63% | +5 p.p. | | **Net Loss** | $(5) million | $(11) million | Improved by 55% | | **Adjusted EBITDA Loss** | $(0.2) million | $(6.8) million | Improved by 97% | - The company's performance was driven by tailwinds in cardiometabolic care and the effective commercialization of its GLP-1 Care Track[3](index=3&type=chunk) - Omada announced a new AI-agent, OmadaSpark, designed to deliver real-time motivational interviewing and nutrition education to members, highlighting its focus on leveraging artificial intelligence[4](index=4&type=chunk) [Financial Outlook and Corporate Developments](index=2&type=section&id=Financial%20Outlook%20and%20Corporate%20Developments) The company issued its financial outlook for the full year ending December 31, 2025, projecting revenue between $235 million and $241 million, and strengthened its balance sheet by fully repaying its outstanding term loan and revolving line of credit in July 2025 Full Year 2025 Financial Outlook | Metric | Guidance Range | | :--- | :--- | | **Revenue** | $235 million to $241 million | | **Adjusted EBITDA Loss** | $9 million to $5 million | - On July 31, 2025, Omada fully repaid its term loan facility and revolving line of credit, totaling approximately **$31.4 million** in principal and accrued interest, which will reduce future interest expense and eliminate related debt covenants[7](index=7&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section details the company's financial position, operational results, and cash flows via consolidated statements [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, Omada's balance sheet shows substantial liquidity growth, with cash and cash equivalents rising to **$223.1 million** from **$76.4 million** due to IPO proceeds, doubling total assets to **$303.0 million** while liabilities remained stable Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $223,146 | $76,392 | | **Total current assets** | $271,105 | $113,059 | | **Total assets** | $302,971 | $150,892 | | **Total current liabilities** | $57,988 | $53,953 | | **Total liabilities** | $88,757 | $86,261 | | **Total stockholders' equity (deficit)** | $214,214 | $(384,403) | [Consolidated Statements of Operations](index=7&type=section&id=Consolidated%20Statements%20of%20Operations) For Q2 2025, total revenue increased **49%** to **$61.4 million**, with gross profit growing **62%** to **$40.3 million**, significantly narrowing operating and net losses to **$4.3 million** and **$5.3 million** respectively, reflecting improved operational leverage Q2 Statement of Operations Highlights (in thousands, except per-share data) | Account | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | **Total revenue** | $61,371 | $41,212 | +49% | | **Gross profit** | $40,306 | $24,834 | +62% | | **Total operating expenses** | $44,650 | $34,871 | +28% | | **Operating loss** | $(4,344) | $(10,037) | +57% | | **Net loss** | $(5,311) | $(10,692) | +50% | | **Net loss per share** | $(0.24) | $(1.40) | +83% | [Consolidated Statements of Cash Flows](index=9&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash used in operating activities improved to **$13.3 million**, with financing activities providing **$162.5 million** from the IPO, resulting in a net cash increase of **$146.8 million** - The company received **$160.5 million** in net proceeds from its initial public offering during the first six months of 2025[24](index=24&type=chunk) Six-Month Cash Flow Summary (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(13,260) | $(28,748) | | **Net cash used in investing activities** | $(2,499) | $(1,826) | | **Net cash provided by (used in) financing activities** | $162,513 | $(898) | | **Net increase (decrease) in cash** | $146,754 | $(31,472) | | **Cash at end of period** | $223,146 | $84,171 | [Non-GAAP Financial Measures and Reconciliations](index=11&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Reconciliations) This section reconciles GAAP to non-GAAP financial measures, providing insights into the company's operational performance [Reconciliation of GAAP to Non-GAAP Measures](index=11&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) This section details the reconciliation from GAAP to non-GAAP metrics, showing Adjusted EBITDA loss significantly improved to **$0.2 million** in Q2 2025, non-GAAP gross margin expanded to **67.7%**, and free cash flow outflow improved to **$15.8 million** for the first six months Reconciliation of GAAP Net Loss to Adjusted EBITDA (in thousands) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **GAAP net loss** | $(5,311) | $(10,692) | | **Adjusted EBITDA** | $(161) | $(6,786) | | **Adjusted EBITDA margin** | (0.3)% | (16.5)% | Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (in thousands) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **GAAP gross profit** | $40,306 | $24,834 | | **Non-GAAP gross profit** | $41,564 | $25,894 | | **GAAP gross margin** | 65.7% | 60.3% | | **Non-GAAP gross margin** | 67.7% | 62.8% | Reconciliation of Net Cash to Free Cash Flow (in thousands) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(13,260) | $(28,748) | | **Free Cash Flow** | $(15,759) | $(30,574) |
13只看涨+2只看跌!大摩揭秘二季度机会,标普每股盈利或增5%
贝塔投资智库· 2025-07-23 04:15
Core Viewpoint - Morgan Stanley's strategy team highlights 15 stocks with short-term catalytic potential, indicating that S&P 500 index earnings growth in Q2 may exceed expectations [1] Earnings Expectations - The market anticipates a 5% year-over-year increase in S&P 500 Q2 earnings per share and over 4% revenue growth, but actual growth may be stronger [1] - The seven major tech companies are expected to see a 14% increase in net profit, while the remaining 493 constituents may experience a 3% decline [1] - Despite analysts lowering earnings expectations from April to May, the earnings revision has rebounded from -25% to approximately 1%, suggesting Q2 earnings will likely exceed expectations, aligning with the historical average of 4%-5% [1] Recommended Stocks - **argenx SE (ARGX.US)**: undervalued R&D pipeline, target price $700 [2] - **Atlassian (TEAM.US)**: continuous revenue growth potential over 20% and expected margin expansion, target price $320 [3] - **Chewy (CHWY.US)**: benefits from marketing and product optimization, expected revenue to maintain or exceed Q1 levels, target price $50 [4] - **CVS Health (CVS.US)**: advantages from competitor store closures and growth in pharmacy benefit management, target price $80 [4] - **DraftKings (DKNG.US)**: potential earnings inflection point in Q2, with actual licensing rates offsetting tax and regulatory pressures, target price $52 [4] - **Eaton Corporation (ETN.US)**: benefits from improved profit margins in U.S. electrical business, target price $375 [5] - **Eli Lilly (LLY.US)**: core products Mounjaro and Zepbound expected to contribute $8.2 billion in revenue, exceeding expectations may lead to 2025 guidance upgrades, target price $1,135 [5] - **F5 (FFIV.US)**: positive outlook due to demand growth in cloud and load balancing products, target price $305 [6] - **NVIDIA (NVDA.US)**: strong end-user demand and accelerated shipments of rack-level products supporting supply-side growth, target price $170 [7] - **Omada Health (OMDA.US)**: operational leverage through technology empowerment and multi-disease sales, target price $25 [8] - **Southwest Airlines (LUV.US)**: potential stock rebound if internal guidance is met and baggage fee impacts are confirmed as limited, target price $38 [9] - **Valley National Bank (VLY.US)**: expected net interest income growth of 3% quarter-over-quarter, target price $11 [10] - **Western Digital (WDC.US)**: undervalued gross margin expansion prospects, target price $85 [11] Cautious Outlook - **National Storage Affiliates Trust (NSA.US)**: cautious due to expected funds from operations (FFO) per share being below market and company guidance, target price $30 [12] - **Teradyne (TER.US)**: revenue and earnings per share forecasts for FY2026 are 7% and 14% below Wall Street expectations, target price $74 [13] Summary - Overall, Morgan Stanley's recommendations combine company fundamentals, industry trends, and market sentiment, providing diversified options for investors [14]